Literature DB >> 8358058

Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil.

C C Liaw1, S J Liaw, C H Wang, M C Chiu, J S Huang.   

Abstract

Hyperammonemic encephalopathy has been reported in patients receiving chemotherapy (CT). It is characterized by abrupt alteration in mental status with markedly elevated plasma ammonium levels in the absence of obvious liver disease. This paper reports seven patients who developed transient hyperammonemia during chemotherapy. The regimens all included continuous infusion of high-dose 5-fluorouracil (5-FU). The onset of hyperammonemic encephalopathy was 1.5-4 days after the start of CT. Five cases had infection and six had prerenal azotemia at the time of hyperammonemia. After management, plasma ammonium levels all returned to the normal range within 2 days. Except for one persistent coma, status of consciousness cleared completely. The true mechanism of transient hyperammonemia is unclear. The excess production of ammonium due to metabolites of 5-FU added to precipitating factors such as infection, hypovolemia or constipation may be the explanation for transient hyperammonemia in our study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358058     DOI: 10.1097/00001813-199306000-00003

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Chemotherapy in a Breast Cancer Patient Heterozygous Carrier of Ornithine Transcarbamylase Deficiency.

Authors:  Magda Palka-Kotlowska; Luis Cabezón-Gutiérrez; Sara Custodio-Cabello; PIlar Quijada-Fraile; Silvia Chumillas-Calzada
Journal:  Cureus       Date:  2020-05-26

Review 2.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

Review 3.  Hyperammonemia syndrome in immunosuppressed individuals.

Authors:  Scott C Roberts; Waleed Malik; Michael G Ison
Journal:  Curr Opin Infect Dis       Date:  2022-06-01       Impact factor: 4.968

4.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

5.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

6.  A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity.

Authors:  Keiki Nagaharu; Kenji Ikemura; Yoshiki Yamashita; Hiroyasu Oda; Mikiya Ishihara; Yumiko Sugawara; Satoshi Tamaru; Toshiro Mizuno; Naoyuki Katayama
Journal:  Case Rep Oncol Med       Date:  2016-04-19

7.  Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.

Authors:  Yoshinao Ozaki; Hirotaka Imamaki; Aki Ikeda; Mitsuaki Oura; Shunsaku Nakagawa; Taro Funakoshi; Shigeki Kataoka; Yoshitaka Nishikawa; Takahiro Horimatsu; Atsushi Yonezawa; Takeshi Matsubara; Motoko Yanagita; Manabu Muto; Norihiko Watanabe
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-03       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.